Abstract
Secretory phospholipases A2 (sPLA2s) are a subfamily of lipolytic enzymes which hydrolyze the acyl bond at the sn-2 position of glycerophospholipids to produce free fatty acids and lysophospholipids. These products are precursors of bioactive eicosanoids and platelet-activating factor (PAF). The hydrolysis of membrane phospholipids by PLA2 is a rate-limiting step for generation of eicosanoids and PAF. To date, more than 10 isozymes of sPLA2 have been found in the mammalian central nervous system (CNS). Under physiological conditions, sPLA2s are involved in diverse cellular responses, including host defense, phospholipid digestion and metabolism. However, under pathological situations, increased sPLA2 activity and excessive production of free fatty acids and their metabolites may lead to inflammation, loss of membrane integrity, oxidative stress, and subsequent tissue injury. Emerging evidence suggests that sPLA2 plays a role in the secondary injury process after traumatic or ischemic injuries in the brain and spinal cord. Importantly, sPLA2 may act as a convergence molecule that mediates multiple key mechanisms involved in the secondary injury since it can be induced by multiple toxic factors such as inflammatory cytokines, free radicals, and excitatory amino acids, and its activation and metabolites can exacerbate the secondary injury. Blocking sPLA2 action may represent a novel and efficient strategy to block multiple injury pathways associated with the CNS secondary injury. This review outlines the current knowledge of sPLA2 in the CNS with emphasis placed on the possible roles of sPLA2 in mediating CNS injuries, particularly the traumatic and ischemic injuries in the brain and spinal cord.
Keywords: Phospholipases A, spinal cord injury, ischemia, excitatory amino acids, reactive oxygen species, inflammation, lipid metabolism, cytokines
CNS & Neurological Disorders - Drug Targets
Title: Role of Secretory Phospholipase A2 in CNS Inflammation: Implications in Traumatic Spinal Cord Injury
Volume: 7 Issue: 3
Author(s): W. Lee Titsworth, Nai-Kui Liu and Xiao-Ming Xu
Affiliation:
Keywords: Phospholipases A, spinal cord injury, ischemia, excitatory amino acids, reactive oxygen species, inflammation, lipid metabolism, cytokines
Abstract: Secretory phospholipases A2 (sPLA2s) are a subfamily of lipolytic enzymes which hydrolyze the acyl bond at the sn-2 position of glycerophospholipids to produce free fatty acids and lysophospholipids. These products are precursors of bioactive eicosanoids and platelet-activating factor (PAF). The hydrolysis of membrane phospholipids by PLA2 is a rate-limiting step for generation of eicosanoids and PAF. To date, more than 10 isozymes of sPLA2 have been found in the mammalian central nervous system (CNS). Under physiological conditions, sPLA2s are involved in diverse cellular responses, including host defense, phospholipid digestion and metabolism. However, under pathological situations, increased sPLA2 activity and excessive production of free fatty acids and their metabolites may lead to inflammation, loss of membrane integrity, oxidative stress, and subsequent tissue injury. Emerging evidence suggests that sPLA2 plays a role in the secondary injury process after traumatic or ischemic injuries in the brain and spinal cord. Importantly, sPLA2 may act as a convergence molecule that mediates multiple key mechanisms involved in the secondary injury since it can be induced by multiple toxic factors such as inflammatory cytokines, free radicals, and excitatory amino acids, and its activation and metabolites can exacerbate the secondary injury. Blocking sPLA2 action may represent a novel and efficient strategy to block multiple injury pathways associated with the CNS secondary injury. This review outlines the current knowledge of sPLA2 in the CNS with emphasis placed on the possible roles of sPLA2 in mediating CNS injuries, particularly the traumatic and ischemic injuries in the brain and spinal cord.
Export Options
About this article
Cite this article as:
Titsworth Lee W., Liu Nai-Kui and Xu Xiao-Ming, Role of Secretory Phospholipase A2 in CNS Inflammation: Implications in Traumatic Spinal Cord Injury, CNS & Neurological Disorders - Drug Targets 2008; 7 (3) . https://dx.doi.org/10.2174/187152708784936671
DOI https://dx.doi.org/10.2174/187152708784936671 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modifying Radiation Damage
Current Drug Targets Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders
CNS & Neurological Disorders - Drug Targets Recent Approaches for Studying the Role of Glia
CNS & Neurological Disorders - Drug Targets Resilient Brain Aging: Characterization of Discordance between Alzheimer’s Disease Pathology and Cognition
Current Alzheimer Research The Vanilloid Agonist Resiniferatoxin for Interventional-Based Pain Control
Current Topics in Medicinal Chemistry Context-dependent Action of Transforming Growth Factor β Family Members on Normal and Cancer Stem Cells
Current Pharmaceutical Design Novel Promising Therapeutic Agents in Multiple Sclerosis
Recent Patents on Inflammation & Allergy Drug Discovery Patents Relating to the Application of Autologous Bone Marrow-Derived Mesenchymal Stromal Cell and Whole Marrow Transplantation for Neurodegenerative Diseases: A Review
Recent Patents on Regenerative Medicine Mechanisms of Neuronal Injury and Death in HIV-1 Associated Dementia
Current HIV Research Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis
Current Pharmaceutical Design Treating Asthma as a Neuroelectrical Disorder
Inflammation & Allergy - Drug Targets (Discontinued) Breakthrough Pain
Current Drug Therapy Antioxidant Activity of Galantamine and Some of its Derivatives
Current Medicinal Chemistry Peptide modules for overcoming barriers of nucleic acids transport to cells
Current Topics in Medicinal Chemistry Agonists of the Tissue-Protective Erythropoietin Receptor in the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry MicroRNAs: Modulators of Cell Identity, and their Applications in Tissue Engineering
MicroRNA Cholinergic Treatment of Traumatic Brain Injury
Current Drug Therapy Transgenic Mouse Models of Alzheimer Disease: Developing a Better Model as a Tool for Therapeutic Interventions
Current Pharmaceutical Design Patent Selections
Recent Patents on Biomedical Engineering (Discontinued) Omega-3 Nutrition Therapy for the Treatment of Diabetic Sensorimotor Polyneuropathy
Current Diabetes Reviews